Cd-ISTAb is an engineered antibody for treatment of C. difficile infections (CDI). The strategy is based on a novel technology that uses Infection Site Targeted neutralizing anti-toxin Antibodies (ISTAb). ISTAbs are directed to the site of infection through specific phage-derived cell wall targeting (CWT) domains that bind specific bacterial species.
ISTABs unique properties:
Cd-ISTAb is a cocktail of two potent antibodies that neutralize C. difficile Toxin A (TcdA) and TcdB) and are targeted to the surface of bacteria.